Hiroyuki Ogasawara

Dr. Hiroyuki Ogasawara

Japan Tobacco Inc., Pharmaceutical Frontier Research Laboratories, Central Pharmaceutical Research Insti-tute
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in Cells
Verified
Journal Article
Open access
PDF file
HOHiroyuki Ogasawara
Hiroyuki Ogasawara
MNMasato Noguchi
Masato Noguchi
Mast cells (MCs) act as primary effectors in inflammatory and allergic reactions by releasing intracellularly-stored inflammatory mediators in diseases. The two major pathways for MC activation are known to be immunoglobulin E (IgE)-dependent and -independent. Although IgE-dependent signaling is the main pathway to MC activation, IgE-independent pathways have also been found to serve pivotal roles in the pathophysiology of various inflammatory conditions. Recent studies have shown that human and mouse MCs express several regulatory receptors such as toll-like receptors (TLRs), CD48, C300a, and GPCRs, including mas-related GPCR-X2 (MRGPRX2). MRGPRX2 has been reported as a novel GPCR that is expressed in MCs activated by basic secretagogues, neurokinin peptides, host defense antimicrobial peptides, and small molecule compounds (e.g., neuromuscular blocking agents) and leads to MC degranulation and eicosanoids release under in vitro experimental condition. Functional analyses of MRGPRX2 and Mrgprb2 (mouse ortholog) indicate that MRGPRX2 is involved in MC hypersensitivity reactions causing neuroinflammation such as postoperative pain, type 2 inflammation, non-histaminergic itch, and drug-induced anaphylactic-like reactions. In this review, we discuss the roles in innate immunity through functional studies on MRGPRX2-mediated IgE-independent MC activation and also the therapeutic potential of MRGPRX2 inhibitors on allergic and inflammatory diseases.

12 July 2019 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
HOHiroyuki Ogasawara
Hiroyuki Ogasawara
MFMasahiro Furuno
Masahiro Furuno
KEKoji Edamura
Koji Edamura
MNMasato Noguchi
Masato Noguchi

1 March 2020 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
HOHiroyuki Ogasawara
Hiroyuki Ogasawara
MFMasahiro Furuno
Masahiro Furuno
KEKoji Edamura
Koji Edamura
MNMasato Noguchi
Masato Noguchi
The eosinophil granule proteins, major basic protein (MBP) and eosinophil cationic protein (ECP), activate mast cells during inflammation; however the mechanism responsible for this activity is poorly understood. We found that some theoretical tryptase-digested fragments of MBP and ECP induced degranulation of human cord blood-derived mast cells (HCMCs). The spectrum of activities of these peptides in HCMCs coincided with intracellular Ca2+ mobilization activities in Mas-related G-protein coupled receptor family member X2 (MRGPRX2)-expressing HEK293 cells. Two peptides corresponding to MBP residues 99-110 (MBP (99-110)) and ECP residues 29-45 (ECP (29-45)), respectively, induced degranulation of HCMCs and intracellular Ca2+ mobilization in MRGPRX2-expressing HEK293 cells in a concentration-dependent manner. Stimulation with MBP (99-110) or ECP (29-45) induced the production of prostaglandin D2 by HCMCs. The activities of MBP (99-110) and ECP (29-45) in both HCMCs and MRGPRX2-expressing HEK293 cells were inhibited by MRGPRX2-specific antagonists. In conclusion, these results indicated that MBP and ECP fragments activate HCMCs, and it may occur via MRGPRX2. Our findings suggest that tryptase-digested fragments of eosinophil cationic proteins acting via the MRGPRX2 pathway may further our understanding of mast cell/eosinophil communication.

27 February 2018 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
KTK. Tatemoto
K. Tatemoto
YNY. Nozaki
Y. Nozaki
RTR. Tsuda
R. Tsuda
SKS. Kaneko
S. Kaneko
KTK. Tomura
K. Tomura
TNT. Naito
T. Naito
Mast cells play a central role in inflammatory and allergic reactions by releasing inflammatory mediators through 2 main pathways, immunoglobulin E‐dependent and E‐independent activation. In the latter pathway, mast cells are activated by a diverse range of basic molecules (collectively known as basic secretagogues) through Mas‐related G protein‐coupled receptors (MRGPRs). In addition to the known basic secretagogues, here, we discovered several endogenous protein and enzyme fragments (such as chaperonin‐10 fragment) that act as bioactive peptides and induce immunoglobulin E‐independent mast cell activation viaMRGPRX2 (previously known as MrgX2), leading to the degranulation of mast cells. We discuss the possibility thatMRGPRX2 responds various as‐yet‐unidentified endogenous ligands that have specific characteristics, and propose thatMRGPRX2 plays an important role in regulating inflammatory responses to endogenous harmful stimuli, such as protein breakdown products released from damaged or dying cells.

1 January 1998 in The Journal of Toxicological Sciences
Verified
Journal Article
Open access
PDF file
YMYoshinori Murakami
Yoshinori Murakami
KYKiyomi Yamazaki
Kiyomi Yamazaki
NSNarumi Sakauchi
Narumi Sakauchi
HOHiroyuki Ogasawara
Hiroyuki Ogasawara
NYNoriaki Yamashita
Noriaki Yamashita
KTKiyonori Tauchi
Kiyonori Tauchi
A repeated oral dose toxicity study of methotrexate(MTX)was conducted in order to examine whether the enhancement of MTX toxicity would occur in unilaterally nephrectomized(UNX)rats. UNX rats or sham-treated(SHAM)rats received dosages of 0, 0.06, 0.2 or 0.6 mg/kg/day(control animals received physiological saline). Toxic effects of MTX observed in this study were not different from studies already conducted, i.e., myelo- and lympho-toxicity, gastrointestinal toxicity, hepatotoxicity, pulmonary toxicity and renal toxicity were evident in the animals given MTX. Toxic effects of MTX in the UNX rats were more severe than those in the SHAM rats;a higher number of dead and moribund animals was observed among the UNX rats, and abnormal clinical signs appeared a few days earlier in the UNX rats. In the hematological examination, a decreased number of the blood cells in the UNX rats was observed at the lower dose level as compared to SHAM rats. The nontoxic dose of MTX in SHAM rats and UNX rats was 0.06mg/kg/day and below 0.06mg/kg/day, respectively. According to the results of a toxicokinetic examination conducted in the animals receiving 0.2mg/kg/day, AUC and T1/2terminal of MTX in the UNX rats were higher than those of SHAM rats. It was considered that the enhancement of the MTX toxicity in UNX rats was caused by the longer exposure of MTX in UNX rats. Serum UN and Cr of the UNX rats receiving physiological saline were higher than those of the corresponding SHAM rats, which suggested a slightly decreased GFR had been induced in UNX rats in this study. However, decreased PSP excretion was not observed in the UNX rats and urine volume of the UNX rats was equivalent to that of SHAM rats. Thus, it was considered that vicarious hypertrophy occurred in the residual kidney and decreased renal function was not evident in the UNX rats. This study demonstrated that the enhancement of toxicity of MTX had occurred even though a decreased renal function was not evident.

1 April 2021 in iScience
Verified
Journal Article
Open access
MWMitsuo Wada
Mitsuo Wada
KYKayo Yukawa
Kayo Yukawa
HOHiroyuki Ogasawara
Hiroyuki Ogasawara
KSKoichi Suzawa
Koichi Suzawa
TMTatsuya Maekawa
Tatsuya Maekawa
Takashi MikiTakashi Miki
Takashi Miki
Gpr52 is an orphan G-protein-coupled receptor of unknown physiological function. We found that Gpr52-deficient (Gpr52−/−) mice exhibit leanness associated with reduced liver weight, decreased hepatic de novo lipogenesis, and enhanced insulin sensitivity. Treatment of the hepatoma cell line HepG2 cells with c11, the synthetic GPR52 agonist, increased fatty acid biosynthesis, and GPR52 knockdown (KD) abolished the lipogenic action of c11. In addition, c11 induced the expressions of lipogenic enzymes (SCD1 and ELOVL6), whereas these inductions were attenuated by GPR52-KD. In contrast, cholesterol biosynthesis was not increased by c11, but its basal level was significantly suppressed by GPR52-KD. High-fat diet (HFD)-induced increase in hepatic expression of Pparg2 and its targets (Scd1 and Elovl6) was absent in Gpr52−/− mice with alleviated hepatosteatosis. Our present study showed that hepatic GPR52 promotes the biosynthesis of fatty acid and cholesterol in a ligand-dependent and a constitutive manner, respectively, and Gpr52 participates in HFD-induced fatty acid synthesis in liver.